Matthew Li

Matthew Li is Biomedical Scientist and Engineer with over 14 years of experience across an array of areas in the academic and industrial biotech field including CGT R&D and manufacturing, translational medical device development, and clinical research. He is currently a Director at Tome Biosciences driving cell therapy CMC strategies. He has held roles at Vor Biopharma and Takeda engaging across the CGT value chain interfacing with research, development, manufacturing, quality, regulatory, clinical, business development, and commercial taking an integrative approach to address challenges across the life cycle of a therapy. Matthew holds a PhD in Medical Engineering and Medical Physics from the joint Health Sciences and Technology program of Massachusetts Institute of Technology and Harvard Medical School.